Hepatic Artery Infusion Chemotherapy for Liver Malignancy

被引：29

作者：

Leal, Julie N. ^{[1
]}

Kingham, T. Peter ^{[1
]}

机构：

[1] Mem Sloan Kettering Canc Ctr, Dept Surg, Div Hepatopancreatobiliary Surg, New York, NY 10065 USA

来源：

SURGICAL ONCOLOGY CLINICS OF NORTH AMERICA | 2015年 / 24卷 / 01期

关键词：

Regional therapy; Liver-directed therapy; Primary liver cancer; Liver metastases; METASTATIC COLORECTAL-CARCINOMA; PROSPECTIVE RANDOMIZED-TRIAL; CLINICAL-PHARMACOLOGICAL EVALUATION; QUALITY-OF-LIFE; PHASE-I TRIAL; REGIONAL CHEMOTHERAPY; INTRAARTERIAL FLOXURIDINE; TECHNICAL CONSIDERATIONS; SYSTEMIC CHEMOTHERAPY; IMPLANTABLE PUMP;

D O I：

10.1016/j.soc.2014.09.005

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

To date, hepatic artery infusion (HAI) chemotherapy has primarily been investigated in the setting of colorectal cancer liver metastases (CRLM). Few studies have been conducted in North America regarding HAI chemotherapy for primary liver cancers (PLC) or noncolorectal liver metastases (non-CRLM). Despite decades of evaluation, controversy surrounding the use of HAI chemotherapy still exists. In this article the methods of HAI chemotherapy delivery, technical aspects of catheter and pump insertion, and specific complications of HAI chemotherapy are discussed. Outcomes of clinical trials and reviews of HAI chemotherapy in the setting of CRLM, PLC, and non-CRLM are evaluated.

引用

页码：121 / +

页数：29

共 92 条

[1] Alternating Systemic and Hepatic Artery Infusion Therapy for Resected Liver Metastases From Colorectal Cancer: A North Central Cancer Treatment Group (NCCTG)/National Surgical Adjuvant Breast and Bowel Project (NSABP) Phase II Intergroup Trial, N9945/CI-66 [J].